Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/8/2015
2044
mi
from 91732
Cleveland, OH
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Lake/University Ireland Cancer Center
2044
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/8/2015
2041
mi
from 91732
Cleveland, OH
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
UHHS Chagrin Highlands Medical Center
2041
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/8/2015
2028
mi
from 91732
Cleveland, OH
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Southwest General Health Center
2028
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/8/2015
2020
mi
from 91732
Cleveland, OH
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
UHHS Westlake Medical Center
2020
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/8/2015
2036
mi
from 91732
Cleveland, OH
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/8/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  10/8/2015
2586
mi
from 91732
Rockland, MA
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/8/2015
Please Contact U.S. Medical Information Located in
2586
mi
from 91732
Rockland, MA
Click here to add this to my saved trials
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  10/8/2015
5783
mi
from 91732
Darmstadt,
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 10/8/2015
Please contact the Merck KGaA Communication Center Located in
5783
mi
from 91732
Darmstadt,
Click here to add this to my saved trials
2036
mi
from 91732
Cleveland, OH
University Hospitals Seidman Cancer Center
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens
Status: Enrolling
Updated:  10/8/2015
2036
mi
from 91732
Cleveland, OH
Identifying Early Lung Cancer Cells in Malignant Pleural Effusion Samples From Patients With Primary Lung Cancer
Isolation and Identification of Lung Cancer Precursor Cells From Malignant Pleural Effusion Specimens
Status: Enrolling
Updated: 10/8/2015
University Hospitals Seidman Cancer Center
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/13/2015
1730
mi
from 91732
Chicago, IL
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
University of Chicago Medical Center
1730
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/13/2015
372
mi
from 91732
Davis, CA
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
University of California Davis
372
mi
from 91732
Davis, CA
Click here to add this to my saved trials
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/13/2015
11
mi
from 91732
Los Angeles, CA
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
University of Southern California Health Sciences Campus
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/13/2015
8
mi
from 91732
South Pasadena, CA
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
City of Hope Medical Group
8
mi
from 91732
South Pasadena, CA
Click here to add this to my saved trials
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  10/13/2015
2277
mi
from 91732
Bethesda, MD
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 10/13/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated:  10/15/2015
1357
mi
from 91732
Houston, TX
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy
Phase II/Pharmacodynamic Study of the γ-secretase Inhibitor RO4929097 in Patients Who Have Recently Completed Front-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Status: Enrolling
Updated: 10/15/2015
M D Anderson Cancer Center
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Status: Enrolling
Updated:  10/17/2015
2434
mi
from 91732
New York, NY
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
A Phase 2 Trial of Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Status: Enrolling
Updated: 10/17/2015
Memorial Sloan Kettering Cancer Center
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1339
mi
from 91732
Fort Smith, AR
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Saint Edward Mercy Medical Center
1339
mi
from 91732
Fort Smith, AR
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
16
mi
from 91732
Anaheim, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Pacific Cancer Medical Center
16
mi
from 91732
Anaheim, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
13
mi
from 91732
Glendale, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Glendale Adventist Medical Center
13
mi
from 91732
Glendale, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
11
mi
from 91732
Los Angeles, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Norris Cancer Hospital
11
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
7
mi
from 91732
Montebello, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Clinical Trials and Research Associates, Inc.
7
mi
from 91732
Montebello, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
326
mi
from 91732
Stockton, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Stockton Hematology Oncology Medical Group, Inc.
326
mi
from 91732
Stockton, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2121
mi
from 91732
Brooksville, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Pasco Hernando Oncology Associates P.A
2121
mi
from 91732
Brooksville, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2114
mi
from 91732
New Port Richey, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Pasco Hernando Oncology Associates, PA
2114
mi
from 91732
New Port Richey, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2183
mi
from 91732
Ormond Beach, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Florida Hospital Memorial System
2183
mi
from 91732
Ormond Beach, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1630
mi
from 91732
Centralia, IL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Southern Illinois Hematology/Oncology
1630
mi
from 91732
Centralia, IL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1726
mi
from 91732
Chicago, IL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Rush University Medical Center
1726
mi
from 91732
Chicago, IL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1701
mi
from 91732
Joliet, IL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Joliet Oncology-Hematology Associates, Ltd.
1701
mi
from 91732
Joliet, IL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1626
mi
from 91732
Houma, LA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Leonard J. Chabert Medical Center
1626
mi
from 91732
Houma, LA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2298
mi
from 91732
Baltimore, MD
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Sinai Hospital of Baltimore
2298
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1790
mi
from 91732
Saint Joseph, MI
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Oncology Care Associates, PLLC
1790
mi
from 91732
Saint Joseph, MI
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
949
mi
from 91732
Billings, MT
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Deaconess Billings Clinic
949
mi
from 91732
Billings, MT
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1165
mi
from 91732
Hastings, NE
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Nebraska Cancer Care, LLC
1165
mi
from 91732
Hastings, NE
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1256
mi
from 91732
Lincoln, NE
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Southeast Nebraska Cancer Center
1256
mi
from 91732
Lincoln, NE
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2435
mi
from 91732
Nyack, NY
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Hematology Oncology Associates of Rockland
2435
mi
from 91732
Nyack, NY
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2101
mi
from 91732
Charlotte, NC
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Carolinas Hematology-Oncology
2101
mi
from 91732
Charlotte, NC
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1886
mi
from 91732
Middletown, OH
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Signal Point Clinical Research Center, LLC
1886
mi
from 91732
Middletown, OH
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1256
mi
from 91732
Tulsa, OK
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Southwestern Regional Medical Center
1256
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1195
mi
from 91732
Fort Worth, TX
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
John Peter Smith Center for Cancer Care
1195
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1195
mi
from 91732
Fort Worth, TX
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
The Center for Cancer and Blood Disorders
1195
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
13
mi
from 91732
Los Angeles, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
92
mi
from 91732
Rancho Mirage, CA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Desert Hematology Oncology Medical Group, Inc
92
mi
from 91732
Rancho Mirage, CA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
824
mi
from 91732
Denver, CO
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Colorado Cancer Center
824
mi
from 91732
Denver, CO
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2320
mi
from 91732
Miami, FL
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Miami, Sylvester Comprehensive Cancer Center
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1955
mi
from 91732
Hazard, KY
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Kentucky Cancer Center
1955
mi
from 91732
Hazard, KY
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1648
mi
from 91732
Metarie, LA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Hematology and Oncology Specialists, LLC
1648
mi
from 91732
Metarie, LA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2301
mi
from 91732
Baltimore, MD
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Maryland, Marlene and Steward Greenbaum Cancer Center
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
2570
mi
from 91732
Burlington, MA
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Lahey Clinic
2570
mi
from 91732
Burlington, MA
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1510
mi
from 91732
Minneapolis, MN
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
University of Minnesota Physicians Masonic Cancer Center
1510
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated:  10/19/2015
1573
mi
from 91732
Saint Louis, MO
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Status: Enrolling
Updated: 10/19/2015
Saint Louis University Cance Center
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials